News
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback